STOCK TITAN

Alpine Immune Sc Stock Price, News & Analysis

ALPN NASDAQ

Company Description

Introduction

Alpine Immune Sciences (ALPN) is a biopharmaceutical company with a strong foundation in immunology and recombinant protein-based immunotherapies. Established in 2015 by a team of experts instrumental in achieving the world's first FDA-approved cancer immunotherapy, the company leverages its deep understanding of the immune system to develop innovative treatment strategies for complex immunological disorders.

Foundational Expertise and Historical Background

Founded by pioneers in the field, Alpine Immune Sciences was created to harness critical scientific insights into the immune synapse—the intricate communication network of immune cells. Drawing on years of specialized expertise, the founding team transformed challenging immunological concepts into therapeutic strategies, setting the stage for multiple research and development programs. The company’s scientific roots lie in the groundbreaking work that led to the approval of a revolutionary cancer immunotherapy, marking a significant milestone in the field and demonstrating their commitment to advancing patient care.

Core Business Areas

The company is focused on developing a portfolio of products aimed at modulating the immune system for therapeutic benefits. Its core areas include:

  • Cancer Immunotherapy: Utilizing sophisticated recombinant protein techniques to fine-tune immune responses against cancer cells.
  • Autoimmune Disorders: Designing solutions to recalibrate dysregulated immune mechanisms that underlie autoimmune diseases, thereby aiming to restore normal immune functioning.
  • Other Immunological Conditions: Exploring therapeutic avenues for other diseases that involve complex immune system interactions.

Operational Excellence and Business Model

Alpine Immune Sciences employs a research-driven business model, focusing heavily on preclinical and clinical development. The company generates revenue through partnerships, licensing arrangements, and collaborative research agreements that leverage its proprietary technology. Its operational model is built on a foundation of detailed scientific inquiry and rigorous clinical evaluation, which helps to cultivate a portfolio that is both innovative and scientifically substantiated.

Competitive Positioning and Market Significance

Within the biotech landscape, Alpine Immune Sciences is recognized for its deep scientific roots and pioneering approach to immunotherapy. While operating in a highly competitive market that includes both established biopharmaceutical entities and agile biotech startups, the company differentiates itself through its unique focus on the immune synapse and recombinant protein methodologies. This focus not only underscores its commitment to scientific excellence but also positions it to address multiple therapeutic areas where precise modulation of the immune system is essential.

Technological Innovation and Research Approach

The company’s approach centers on harnessing cutting-edge technology to untangle the complexities of the immune response. By investigating the molecular interactions that dictate immune cell activation and regulation, Alpine Immune Sciences seeks to develop treatments that are both highly targeted and broadly applicable across different immunological conditions. The integration of advanced biotechnology techniques, including protein engineering and targeted delivery systems, is a hallmark of its research and development philosophy.

Industry Impact and Scientific Credibility

Alpine Immune Sciences has built a reputation rooted in meticulous scientific research and a profound understanding of immunological mechanisms. Its work in modulating the immune synapse is reflective of a broader industry trend towards precision medicine and targeted therapeutic strategies. The company’s historical achievements and ongoing research endeavors lend credibility to its expertise, making it a subject of interest among industry analysts and researchers alike.

Summary of Value Proposition

The primary value proposition of Alpine Immune Sciences lies in its distinct ability to translate intricate scientific knowledge into viable treatment options. Its focus on modifying the immune synapse, combined with expertise in recombinant protein-based immunotherapies, enables the company to address complex disease mechanisms with precision. This integration of scientific innovation and practical therapeutic development is at the heart of its business model, underpinning its role in advancing medical research and patient care across cancer, autoimmune disorders, and other immune-mediated conditions.

Conclusion

In summary, Alpine Immune Sciences represents a convergence of scientific innovation and clinical application. Its expertise in immunology and the development of recombinant protein immunotherapies provide it with a unique competitive edge. As it continues to focus on understanding and modulating the immune synapse, the company maintains an important position in biopharmaceutical research, contributing meaningful advancements to the treatment of some of the most challenging diseases in modern medicine.

Stock Performance

$—
0.00%
0.00
Last updated:
-100 %
Performance 1 year
$4.5B
Market Cap
68.6M
Shares outstanding

SEC Filings

No SEC filings available for Alpine Immune Sc.

Financial Highlights

$7,032,000
Revenue (TTM)
-$17,918,000
Net Income (TTM)
-$0.28
Diluted EPS (TTM)
-$27,690,000
Operating Cash Flow
-254.81%
Net Profit Margin
-322.75%
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Alpine Immune Sc (ALPN)?

The current stock price of Alpine Immune Sc (ALPN) is $64.97 as of February 7, 2025.

What is the market cap of Alpine Immune Sc (ALPN)?

The market cap of Alpine Immune Sc (ALPN) is approximately 4.5B.

What is the revenue (TTM) of Alpine Immune Sc (ALPN) stock?

The trailing twelve months (TTM) revenue of Alpine Immune Sc (ALPN) is $7,032,000.

What is the net income of Alpine Immune Sc (ALPN)?

The trailing twelve months (TTM) net income of Alpine Immune Sc (ALPN) is -$17,918,000.

What is the earnings per share (EPS) of Alpine Immune Sc (ALPN)?

The diluted earnings per share (EPS) of Alpine Immune Sc (ALPN) is -$0.28 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Alpine Immune Sc (ALPN)?

The operating cash flow of Alpine Immune Sc (ALPN) is -$27,690,000.

What is the profit margin of Alpine Immune Sc (ALPN)?

The net profit margin of Alpine Immune Sc (ALPN) is -254.81%.

What is the operating margin of Alpine Immune Sc (ALPN)?

The operating profit margin of Alpine Immune Sc (ALPN) is -322.75%.

What is the current ratio of Alpine Immune Sc (ALPN)?

The current ratio of Alpine Immune Sc (ALPN) is 9.56, indicating the company's ability to pay short-term obligations.

What is the operating income of Alpine Immune Sc (ALPN)?

The operating income of Alpine Immune Sc (ALPN) is -$22,696,000.

What is the core focus of Alpine Immune Sciences?

Alpine Immune Sciences focuses on harnessing immunology and recombinant protein-based therapies to develop treatments for cancer, autoimmune disorders, and other immune-related conditions.

How was the company founded?

The company was established in 2015 by a team of experts responsible for the FDA approval of the world’s first cancer immunotherapy, leveraging deep scientific understanding to advance novel treatments.

What are the main therapeutic areas addressed by Alpine Immune Sciences?

The company primarily focuses on cancer immunotherapy and therapies for autoimmune disorders, while also exploring treatment options for other complex immunological conditions.

How does Alpine Immune Sciences differentiate itself in the biotech industry?

The company differentiates itself through its unique expertise in modulating the immune synapse and its application of recombinant protein-based immunotherapies, positioning itself uniquely in a competitive market.

What is the primary technology used by Alpine Immune Sciences?

They utilize advanced biotechnology techniques centered on recombinant protein engineering and targeted modulation of the immune synapse to develop precise immunotherapeutic agents.

How does the company generate revenue?

Alpine Immune Sciences generates revenue through research collaborations, licensing partnerships, and strategic alliances that capitalize on its specialized technology and scientific expertise.

In what way does Alpine Immune Sciences contribute to immunology research?

The company makes significant contributions to immunology research by exploring the intricate dynamics of immune cell interactions, thereby developing targeted therapies that address a range of immune-mediated diseases.

What factors establish the company’s credibility in the biopharmaceutical field?

Its credibility is rooted in the foundational work behind the first FDA-approved cancer immunotherapy, rigorous research methodologies, and the consistent application of advanced immunological science.